Latest posts tagged with #glomcon on Bluesky
🔥 Brilliant session by the legendary Dr. Glassock at the #GlomCon Fellowship!
Limiting #LupusNephritis flares is JUST as important as treatment.
✅ Prevent relapses → ↓ risk of #ESKD
🎯 Goal: Immunological remission (normal complements, neg. anti-dsDNA)
@glomcon.org
Empowering the Next Generation of Nephrologists: Trainee Opportunities in #GlomCon Ecosystem from @asnpublications.bsky.social @glomcon.org @bettercallseeth.bsky.social @saynanorouzi.bsky.social @nephrologista.bsky.social @poyanmehr.org
#Nephpearls #NephSky
👉 pubmed.ncbi.nlm.nih.gov/41105470/
Did you miss #GlomCon Hawaii? Don't worry, I took the hit and flew to Hawaii for a week so I could give all of you a summary of what went down. Read all about it...
I heard of the exercise stress test, the Persantine Cardiolite stress test but until today I was unaware of the Ritz Carlton Stress Test #GlomCon
Roven asked about how fast to update the guidelines. Sounds like he was on the writing panel. How can we keep up?
They are planning on shorter more frequent commentaries. Maybe yearly updates. #GlomCon
Fervenza has been asked about galactose deficient IgA1. He says he is going to be nice but then says he has nothing nice to say about KDIGO.
He says guidelines are always backward looking. No answer about Gd-IgA1 though
#GlomCon
He wrote a 12 page letter criticizing the guidelines last year. He feels they are not timely. Database closed in August 2024.
He discloses that he is the editor of the GN section of UpToDate. He remarks that the editorial staff is much smaller than KDIGO. #GlomCon
Glassock starts with "my mother told me if you have nothing nice to say, keep your moouth shut" He is going to violate those instructions. #GlomCon #KDIGO
Last session of #GlomCon is KDIGO IgA guidelines, What's up with that?
Critical Appraisel of the KDIGO Guidelines
Star studded panel with Glassock, Rovin, Rheualt, Romangnani, and Edgar streaming in from Chicago!
#GlomCon
Outcomes for the rest of the basket should be coming soon-ish. I’m on the writing group but we haven’t met yet. #Glomcon
Results show significant reduction in proteinuria and stable GFR regardless of how effective the reduction of proteinuria (45% of patients achieved <500 mg/d of proteinuria) #GlomCon
Next up Zigakibart in IgAN treated for 76 weeks.
Zigakibart is an April inhibitor (learned how to access the poster slides, so screen grabs rather than photos of the slides)
Title, methods, and table 1 demographics #GlomCon
Barratt then presented phase 2 data on atrasentan in IGAN on subgroups. This was an open label basket trial that looked at a number of diseases, but this is only data from IGAN. Outcome was proteinuria at 12 weeks #GlomCon
Jonathon Barrat up to discuss reduction in urinary biomarkers with sparsanten showing an impressive reduction in infalmmatory and fibrotic factors. Maybe endothelin antagonists are not just hemodynamic #GlomCon
Abstract presentation
52 week results from VALIANT of pegcetacoplan for C3G
68% reductionin protein at 26 weeks
stabilization of GFR (+6.3 ml/min vs placebo)
72% reduction in nephrotic range proteinuria
#GlomCon
KDIGO in 2021 recommended eculizamab for people with more than 1 gram of proteinuria
#GlomCon
Average loss of function is 4 ml/min which is made up of two cohorts, fast loss and slow ross. Possibly genetic, only a small group have pathogenic genes.
20% C3GN
Higher in DDD
#GlomCon
Next up up is Dr. Sperati to discuss My approach to C3 Glomerulopathy #GlomCon
Iptacopan is a factor B inhibitor
oral drug
200 mg bid
primary outcome was proteinuria
12 month data
28 on drug and 36 on placebo
40% reduction in protein at 180 days
remains low through 12 months
placebo group got put on drug after 6 months and they started to do better too!
#GlomCon
now avacopan, publishedin 2025
initially used activity index as primary outcome. I failed. Hints of improved protein and improved GFR. It was a failed trial though. Patients felt fantastic. All felt great (it was only four people). #GlomCon
The there was soluble CR1 therapy, This acts as a sponge to soak up compliment. Worked in mice. Tested in C3GN. aTested in one human before the project was abandoned. #GlomCon
7 years larter another study of eculizumab 6/26 had complete remission and another 6/26 had partial remission. #GlomCon
